COAG COAG
Company Profile ↓Company Overview
COAG (COAG) is a publicly traded company listed on with a market capitalization of $2.21B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 36.2%, reflecting efficient use of shareholder capital.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -31.2%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -31.22% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +47.32% |
| 6 Months: | - |
| 3 Months: | +100.36% |
| 1 Month: | +59.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)61.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 36.2%.
CONS
- Earnings shrank at -31.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 16.56M | 23.61M |
| Operating Income | -16.56M | -23.61M |
| EBITDA | -16.48M | -23.54M |
| Interest Expense | - | - |
| Pretax Income | -15.50M | -22.68M |
| Tax Provision | -190.00K | 12.00K |
| Net Income | -15.31M | -22.69M |
| Diluted EPS | -16.18 | -0.51 |
| R&D Expense | 14.10M | 19.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 50.38M | 70.12M |
| Operating Income | -50.38M | -70.12M |
| EBITDA | -50.13M | -69.81M |
| Interest Expense | - | - |
| Pretax Income | -48.52M | -64.14M |
| Tax Provision | 185.00K | -227.00K |
| Net Income | -48.71M | -63.91M |
| Diluted EPS | -1.77 | -2.33 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 96.28M | 194.78M |
| Current Assets | 93.23M | 192.55M |
| Cash & Equivalents | 74.41M | 87.97M |
| Inventory | - | - |
| Receivables | 1.58M | 2.63M |
| Total Liabilities | 211.55M | 371.42M |
| Current Liabilities | 6.68M | 10.68M |
| Long Term Debt | - | - |
| Total Debt | 1.73M | 1.22M |
| Total Equity | -115.27M | -176.63M |
| Shares Outstanding | 44.19M | 44.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -45.59M | -61.48M |
| Investing Cash Flow | 61.90M | -81.48M |
| Financing Cash Flow | -100.00K | 156.30M |
| Capital Expenditure | -282.00K | -16.00K |
| Free Cash Flow | -45.87M | -61.49M |
| Net Change in Cash | 16.21M | 13.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 42.3% | 36.2% |
| ROCE % | -56.2% | -38.1% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COAG
Hemab Therapeutics (NASDAQ:COAG) Trading Down 4.8% - What's Next? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPMy03YnJqM2Nial9DdEZmWDdfVEJweE5HWDhzMlNiQlRlNy1LOWMxeEpKR0pfazNkVER1bHNJM3Fra0IwblF2NVp6WDN0dEt1Sllpc053NFAtRWVhQkx3Ynk3QkRWU0Rja0RDb2xfZEFRbkM4WmdZR25EekFNbnI0YTZ1WklYUkFjZEllWl…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5KdjVOVWFBTG9HVTZVZXNKUGFEUmQ1WjdLbDRRaXlyTW5hcWpyVFdPMDhYMzg2OVJxSXhsem0zN1BhRG5xRFhtWEZIT2RualVX?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
COAG Stock Price and Chart — NASDAQ:COAG - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE11UFY0eFpaa2wwQ1pXY3B6a0l1Z0RDTjNNOVVEZURGc3JWTjRueF92aFJjTmZUV1diOFNiTVBISTlIWDdILUM2YUIxaEFxeTJvN1BTenB0Vl9GdUMt?oc=5" target="_blank">COAG Stock Price and Chart — NASDAQ:COAG</a…
HEMAB THERAPEUTICS HOLDINGS (COAG) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE9jUlJXcUoxaWcxVXQxQi0yeEEyZERTcGtJdW9Uajd5eC10a3k5cGhyLU9hZlk4THdISmlQNkVrS2lrN3M4Wk9wc0lfSDZuUjVIbzU4?oc=5" target="_blank">HEMAB THERAPEUTICS HOLDINGS (COAG) Stock Price, News & …
Hemab Therapeutics IPO Debut Puts COAG And Pipeline Risks In Focus - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOZkRLNHlvMXM2VGJwN0Z2N2FmTWdzaVlQUk9pc3Y5clFVNFhxQ1I3SlZIWXZma1FOV2tTNERpeDJ4eUptbEtlQ3NNaUtXN0taZjRUWnU0aDFJNzdDWWJSdDQ1STVHeDFFYXh5WjEtU0thYzRkSjFTWFFjeFNOQTdUR3FERUluWVFNNE5TX3…
Hemab Therapeutics Holdings, Inc (COAG) Stock Price Today: $46.41 - Gotrade
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE56RjNYMXdUUDFhUmdpR3JnaDVzMGdvalFoS3BlMFcxbVVnQlVnWmZFWFZKeWt2dUc2WHNiVWNuUURFWTNsTlFMcVluYnhROTFsRjlBYXZaWQ?oc=5" target="_blank">Hemab Therapeutics Holdings, Inc (COAG) Stock Pri…
COAG — Frequently Asked Questions
What is the current share price of COAG?
As of 2026-08-05 17:25 PDT, COAG trades at $50.09 on NASDAQ/NYSE. Its 52-week range is $24.98 to $50.39.
What is the market capitalisation of COAG?
COAG has a market capitalisation of $2.21B on NASDAQ/NYSE.
What is the P/E ratio of COAG?
COAG trades at a trailing price-to-earnings (P/E) ratio of -21.50. Its price-to-book (P/B) ratio is -12.53.
What is the return on equity (ROE) of COAG?
COAG has a return on equity (ROE) of 36.18%. Its return on capital employed (ROCE) is -38.09%.
Is COAG a good stock to buy?
This page provides a data-driven analysis of COAG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.